XSpray Pharma AB
Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company develops Dasynoc, an amorphous version of dasatinib for the treatment of chronic myeloid leukemia (CML)and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib for the treatment of CML; XS008, an axitinib for the tr… Read more
XSpray Pharma AB (XSPRAY) - Total Assets
Latest total assets as of September 2025: Skr820.20 Million SEK
Based on the latest financial reports, XSpray Pharma AB (XSPRAY) holds total assets worth Skr820.20 Million SEK as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
XSpray Pharma AB - Total Assets Trend (2015–2024)
This chart illustrates how XSpray Pharma AB’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
XSpray Pharma AB - Asset Composition Analysis
Current Asset Composition (December 2024)
XSpray Pharma AB's total assets of Skr820.20 Million consist of 29.5% current assets and 70.5% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 26.2% |
| Accounts Receivable | Skr6.49 Million | 0.8% |
| Inventory | Skr20.34 Million | 2.6% |
| Property, Plant & Equipment | Skr79.19 Million | 9.9% |
| Intangible Assets | Skr478.93 Million | 60.1% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how XSpray Pharma AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: XSpray Pharma AB's current assets represent 29.5% of total assets in 2024, a decrease from 88.9% in 2015.
- Cash Position: Cash and equivalents constituted 26.2% of total assets in 2024, down from 79.3% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 60.0% of total assets, an increase from 7.0% in 2015.
- Asset Diversification: The largest asset category is intangible assets at 60.1% of total assets.
XSpray Pharma AB Competitors by Total Assets
Key competitors of XSpray Pharma AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
XSpray Pharma AB - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - XSpray Pharma AB generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - XSpray Pharma AB is currently not profitable relative to its asset base.
XSpray Pharma AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.72 | 1.90 | 16.70 |
| Quick Ratio | 5.93 | 1.51 | 16.70 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr199.34 Million | Skr 47.96 Million | Skr 311.20 Million |
XSpray Pharma AB - Advanced Valuation Insights
This section examines the relationship between XSpray Pharma AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.57 |
| Latest Market Cap to Assets Ratio | 0.09 |
| Asset Growth Rate (YoY) | 4.1% |
| Total Assets | Skr796.34 Million |
| Market Capitalization | $68.77 Million USD |
Valuation Analysis
Below Book Valuation: The market values XSpray Pharma AB's assets below their book value (0.09 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: XSpray Pharma AB's assets grew by 4.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for XSpray Pharma AB (2015–2024)
The table below shows the annual total assets of XSpray Pharma AB from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr796.34 Million | +4.06% |
| 2023-12-31 | Skr765.26 Million | +30.72% |
| 2022-12-31 | Skr585.43 Million | -6.02% |
| 2021-12-31 | Skr622.90 Million | +2.91% |
| 2020-12-31 | Skr605.30 Million | +51.07% |
| 2019-12-31 | Skr400.67 Million | +28.22% |
| 2018-12-31 | Skr312.49 Million | +93.59% |
| 2017-12-31 | Skr161.41 Million | +211.24% |
| 2016-12-31 | Skr51.86 Million | +246.88% |
| 2015-12-31 | Skr14.95 Million | -- |